SCHEMBL3975657

SCHEMBL3975657

Cc1cc(C)c(C(N)=O)c(Nc2cc(C(C)(C)C)nn2-c2cc(F)ccc2C)n1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
HSD17B10 Q99714 1/20 0.44
MAPK14 Q16539 5/20 0.43
MAPK13 O15264 3/20 0.43
MAPK12 P53778 3/20 0.43
MAPK11 Q15759 3/20 0.43
ALDH1A1 P00352 3/20 0.42
TP53 P04637 1/20 0.42
BLM P54132 1/20 0.42
MAPT P10636 2/20 0.41
KDM4E B2RXH2 3/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 2/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CDK8 P49336 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974472 0.91 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11
SCHEMBL3976307 0.91 MEN1 (0.47) MEN1KMT2AHSD17B10MAPK14MAPK13
SCHEMBL3976174 0.87 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11CDK8
SCHEMBL3979041 0.87 MAPK14 (0.55) MEN1KMT2AHSD17B10MAPK14MAPK13
SCHEMBL3973998 0.85 HSD17B10 (0.44) MEN1KMT2AHSD17B10MAPK14ALDH1A1
SCHEMBL3976330 0.82 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11
SCHEMBL3979965 0.81 HSD17B10 (0.42) MEN1KMT2AHSD17B10ALDH1A1TP53
SCHEMBL3978596 0.81 LMNA (0.49) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL3974011 0.80 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11CDK8
SCHEMBL3974140 0.78 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP MEN1 3766/4885KMT2A 3923/4885HSD17B10 320/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP MEN1 3766/4885KMT2A 3923/4885HSD17B10 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.